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brachytherapy of the prostate, compared to a SSCP. The primary 
objective of this study was to investigate whether a DSCP leads to 
more similarity between an online plan based on TRUS and a post plan 
based on CT, compared with SSCP. The secondary objective was to 
determine whether the post-plan based DVH parameters improved 
using with the DSCP technique compared with the SSCP technique. 
Materials and Methods: In the study 50 consecutive patients with 
prostate cancer were included, who were treated between March 
2008 and March 2010. The first 25 of these patients had their online 
planning based on a SSCP, the plans of the other 25 patients were 
based on a DSCP TRUS. Three weeks after implantation a post 
planning was made based on CT. TRUS online and CT post plan dose 
volume histogram (DVH) parameters, D90 and V100, were compared 
for both groups. Also, the post plan DVH parameters of SSCP were 
compared with DSCP. The possible factors that might influence the 
post plan D90 and V100 were analysed using ANOVA. 
Results:  
 The SSCP and DSCP online mean D90 and V100 were significantly 
larger than post plan mean D90 and V100 (P < 0.01). The post plan 
mean D90 and mean V100 were both non-significantly larger for the 
with SSCP implanted patients, compared to the with DSCP implanted 
patients (P = 0.76 and P = 0.68).  The online-plan D90 and V100 in the 
DSCP group were very similar among the patients, compared to the 
SSCP group. The SD's of the D90 of SSCP and DSCP were 14.2 Gy and 
11.1 Gy and the V100 ranged from 91.5 to 99.1% and from 97.7 to 
99.9%, respectively. ANOVA showed significant impact of prostate 
volume on the post-plan D90 (P<0.01) and V100 (P = 0.02). 
Conclusions: The longer sagittal view of the prostate and surrounding 
tissues with the DSCP enabled better visualisation in one view, which 
resulted in more homogeneous online plans among patients. However, 
the DVH parameters showed that this did not lead to more accurate 
online planning. The TRUS and CT based D90 and V100 showed 
statistical significant difference, whereas the post plan based D90 and 
V100 did not improve with the DSCP technique compared to the SSCP 
technique. Both types of probes are equally accurate for permanent 
prostate brachytherapy treatment planning. The most important 
factor found to influence DVH parameters was the prostate volume. 
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Purpose/Objective: In 3-Tesla MRI image, the seeds and the contours 
of prostate and urethra are clearer than in 1.5-Tesla MRI image. 
Meanwhile, their reliability has been less investigated, and it remains 
unclear which procedure is more reliable. We assessed the 
interobserver variability in 3-Tesla and 1.5-Tesla MRI/CT fusion-based 
postimplant dosimetry of prostate brachytherapy. 
Materials and Methods: Between July 2009 and December 2010, a 
total of 26 consecutive prostate cancer patients underwent 
brachytherapy and 1.5-Tesla MRI and CT (1.5T) were performed on 
day 30. Subsequently, between December 2010 and November 2011, 
another  26 consecutive prostate cancer patients underwent 
brachytherapy and  3-Tesla MRI and CT (3T) were performed on day 
30. All the patients were treated with 144 Gy of brachytherapy alone. 
Two radiation oncologists performed MRI/CT fusion-based postimplant 
dosimetry. The interobserver variability of dose-volume histogram 
(DVH) parameters (prostate D90, prostate V100, prostate V150, 
urethral D5, and urethral V200) was calculated by using Pearson’s 
correlation coefficients. Differences in means of DVH parameters were 
also tested by using a paired t test. 
Results: Pearson’s correlation coefficients of 3T were larger than 
those of 1.5T in all the DVH parameters (prostate D90, 1.5T: 0.66, 3T: 
0.85; prostate V100, 1.5T: 0.63, 3T: 0.68; prostate V150, 1.5T: 0.96, 
3T: 0.98; urethral D5, 1.5T: 0.84, 3T: 0.92; urethral V200, 1.5T: 0.77, 
3T: 0.92). In a paired t test, none of the DVH parameters were 
statistically significant in 3T (0.082≤p≤0.26). In 1.5T, however, 
significant differences were observed in prostate D90, prostate V100, 
and prostate V150 (p<0.001). 
Conclusions: The interobserver variability of 3-Tesla MRI/CT fusion-
based postimplant dosimetry was smaller than that of 1.5-Tesla 
MRI/CT fusion-based postimplant dosimetry, suggesting that the 
former is more reliable among prostate cancer patients undergoing 
brachytherapy. 
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Purpose/Objective: The electromagnetic tracking systems 
(EMTS),initially employed in virtual reality experiments, are more and 
more integrated in several medical protocols. That technology can 
improve the accuracy of physician's gestures from real time tracking 
of positions and orientations of needles or catheters. However, the 
electromagnetic field distortion, due to metallic structures or medical 
devices in the environment, is not negligible and has to be 
characterized. For prostate brachytherapy, there are several metallic 
elements and electronic tools close to the zone of detection: the 
operating table, the needles, the template, the ultra-sound probe 
stabilizer and an important concentration of small seeds in volume of 
interest during low-dose rate (LDR) brachytherapy. The purpose of 
this study is to characterize the performance of the planar field 
generator Aurora (Northern Digital Inc., Waterloo, Canada) as a real-
time, high accuracy needle guidance technology in prostate 
brachytherapy.  
Materials and Methods: All measurements have been recorded in an 
environment free of electromagnetic disturbances. The 
characterization of the planar field generator Aurora from NDI 
included the definition of volume boundaries, the errors calculations 
of position and orientation for the sensor throughout this volume.For 
these measurements the sensor (5 degrees of freedom (5DOF)) was 
integrated into a needle from a biopsy introducer set (PHILIPS 
developed EM system). The needle support could be moved accurately 
with a sub-millimeters displacement (± 0.25mm) everywhere in the 
measurement volume (600 x 600 x 600 mm³) in front of the generator. 
To estimate the accuracy of position, 486 measurements were 
recorded into the volume of interest. In addition, 22 measurement 
points, covering from X to Y degrees, were utilized to evaluate the 
accuracy of orientation measurements. The latter were repeated for 
needle orientations parallel (± 90°)and perpendicular (0°) to the 
central axis of the field generator. 
Results: Results show that the standard deviation on sensor position is 
less than 0.04 mm when needle is located within 26 cm of 
generator,but start increases significantly beyond 35 cm. When needle 
is on volume edges(at 60 cm) the position defined by EMTS is 
underestimated by 16.0±0.6 mm. The errors on the measured 
orientation were low at ±1°, except when the needle is perpendicular 
to the generator, at more than 375 (±1) mm; the error on the 
orientation rises exponentially with distance up to 4.5° at 575 (±1) 
mm. 
Conclusions: Our work shows that the EMTS Aurora planar field 
generator seems to possess the needed accuracy to enable real-time 
needle/catheter guidance for brachytherapy applications. As 
recommended practices, the needle should be parallel with the 
generator plan, and the treatment zone should be ideally kept within 
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the first half of 3D detection volume, no farther than 30-35 cm away 
from the generator.  
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Purpose/Objective: The aim of this study was to obtain equivalent 
doses to radiosensitive organs when applying high-dose-rate (HDR) 
brachytherapy to a localized prostate carcinoma using 60Co or 192Ir 
sources, and in comparison to external-beam radiotherapy (EBRT). 
Materials and Methods: Monte Carlo (MC) simulations in Geant4 were 
performed using a voxelized phantom described in International 
Commission on Radiological Protection (ICRP) Publication 110, which 
reproduces masses and shapes from an adult reference man defined in 
ICRP Publication 89. Point sources of 60Co or 192Ir with photon energy 
spectra corresponding to those exiting their capsules were placed in 
the center of the prostate. Equivalent doses per clinical absorbed 
dose to the prostate were obtained in several radiosensitive organs. 
Values were corrected to account for realistic source dwell times and 
positions throughout the prostate. This was repeated for a 
homogeneous water phantom to assess the adequacy of a 
homogeneous phantom for HDR dose calculations. Brachytherapy 
doses were compared to reported values from three-dimensional 
conformal radiotherapy (3D-CRT), intensity-modulated radiation 
therapy (IMRT), and proton therapy. 
Results: For the nearest organs considered (bladder, rectum, testes, 
small intestine, and colon), equivalent doses given by 60Co source 
were smaller than from 192Ir. As the distance increased, the more 
penetrating gamma-rays produced by 60Co delivered higher equivalent 
doses. Relative to 192Ir, the dose ratio increased up to a factor 5 for 
the brain. Due to the photoelectric effect and the passage of photons 
through different tissues (bone, air, and lungs), differences between 
the heterogeneous and the water phantom became apparent at 
distances larger than 30 cm. Finally, for the closest organs, equivalent 
doses from the three EBRT modalities were within an order of 
magnitude to equivalent doses deposited by both brachytherapy 
sources. However equivalent doses from brachytherapy were up to 
two orders of magnitude smaller than EBRT for the furthest organs. 
Conclusions: According to physical considerations, 60Co appears 
dosimetrically advantageous over 192Ir sources at close distances, but 
not for the furthest organs. On the other hand, equivalent doses to 
distant healthy organs were lower for brachytherapy than the three 
studied EBRT modalities.  
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Purpose/Objective: Evaluation of feasibility and early tolerance of 
interstitial hyperthermia combined with salvage prostate 
brachytherapy in patients with BGI confirmed local recurrence after 
previous external beam radiotherapy. 
Materials and Methods: Between 16th December 2008 and 25th 
October 2012, in the Centre of Oncology in Cracow, 21 patients with 
biopsy confirmed local recurrence of previously irradiated prostate 
cancer were qualified for salvage HDR brachytherapy of the prostate 
combined with interstitial hyperthermia using BSD500 equipment (BSD 
Medical). 55 hyperthermia procedures had been performed out of 
planned 63 (87,3%). The reason for quitting procedure was failure of 
the hyperthermia equipment in 5 cases and only saddle block 
anaesthesia in 3 patients cases. The aim of the hyperthermia 
treatment was to heat (in asynchronous mode in order to protect the 
urethra) the peripheral zone of the prostate to 41 – 43°C for 60 
minutes. All patients were treated with the brachytherapy dose of 30 
Gy in 3 fractions, 10 Gy each, with 3-week intervals between 
fractions. 3D inverse planning under TRUS control was performed 
using SWIFT or ONCENTRA Prostate ® systems, Nucletron™. 
Results: Combined treatment including interstitial hyperthermia and 
HDR brachytherapy is feasible during the period of standard 
subarachnoid anaesthesia for brachytherapy. Mean therapeutic 
hyperthermia duration was 50 minutes (range 30 – 60). Mean 
temperature in the prostate during the procedure was 41,2°C (range 
38.4 –42.9°C), maximal temperature measured in the prostate was 
41,9°C (range 40.4 – 43,4°C), and mean temperature in the rectum 
was 38,5°C (range 37,1 – 42°C) – 20 measurements in rectum were 
done. The most frequent complications in the first 3 months after 
treatment were: nocturia 3x – 28,5%, 4x and more - 38%, weak urine 
stream, G1 - 52%, G2 - 24%, urinary frequency G1 - 38%, G2 - 24%, 
hematuria G1 - 47,5%, G2 - 9,5%, non-bacterial inflammation of the 
urethral or bladder G1 - 38%, urgency G1-38%, G2 - 5%; perineal, 
penile or abdominal pain G1 - 19% (self limiting usually in 24-48 
hours), residual urine G1 - 19%, G2 – 14%, urinary incontinence G1 - 
14%. In 1 patient rectal complications were observed (G2 – 
hemorrhage). We didn't observe early complications in the degree G3 
and G4. 
Conclusions: Early tolerance of interstitial hyperthermia in 
combination with HDR brachytherapy is good. No early grade 3 or 4 
complications were found in the analysed group of patients.The most 
common mild complications were urination frequency, nocturia, 
hematuria and transient weakening of urine stream.  
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Purpose/Objective: The purpose of this study is to demonstrate the 
feasibility and safety of combining a brachytherapy boost with an 
hypofractionated EBRT regiment in prostate cancer treatment and 
compare it to our current standard approach, toxicity wise. 
Materials and Methods: 1050 patients have been treated with 
brachytherapy boost (HDRBB) in our facility, all of which we 
prospectively cumulated treatment data. At follow-ups, patients 
filled-in forms reporting side effects and IPSS scoring. 157 
intermediate risk patients were treated with our standard 
fractionation scheme (Std) (40-44Gy in 20-22 fractions) plus HDRBB 
(15Gy single fraction). An experimental group of 30 patients (Table 1) 
were treated with (Hypo) (36Gy in 12 fractions) and HDRBB. Both 
groups share similar pre implants caracteristics. 
Results: Median IPSS scores at consultation and at 1, 3, 6, 12 months 
after treatments are reported in Table 2 as compared with the FU 
reports of our experimental group. No GI grade 3 or 4 toxicities were 
reported in the later group. Patients benificite of a reduction in 
treatment course up to 13 days of treatments. 
 
 
  Hypo (n = 30) Std (n = 157)
Age (years) Median (Std dev) 66 (±7,27) 65 (±6,46) 
Initial PSA Median (Std dev) 
≤ 10 
> 10 <20 
3,7(±3,17) 
28 (93%) 
2 (6%) 
5,9 ±3,54) 
121 (77%) 
36 (23)% 
Clinical stage T1C 
T2A 
T2B 
21 (70%) 
7 (23%) 
2 (7%) 
97 (61%) 
36 (23%) 
24 (15%) 
Gleason score  7 7 
Risk group  Int Int 
Hormonal therapy  8 (26,7%) 18 (11,5%) 
Table 1 : Population demographics. 
 
Treatment \ Median 
IPSS score 
pre (Std
Dev) 
1 month
(Std Dev) 
3 
months 
(Std 
Dev) 
6 
months 
(Std 
Dev) 
12 
months 
(Std 
Dev) 
Hypo (n= 30) 4 (± 7,07) 10,5 
(±8,12) 
5 
(±8,13) 
6 
(±5,18) 
8 
(±7,37) 
Std (n=157) 6 (±6,67) 10 
(±7,96) 
7 
(±9,97) 
8 
(±8,48) 
9 
(±7,22) 
Table 2 Median IPSS score evolution prior and post treatment. 
 
Conclusions: Hypofractionated Radiation course plus brachytherapy 
boost for prostate cancer seems to benefit our patients in reducing 
the total lenght of their treatment from 23 days to 13 days. More 
importantly, this new regiment did not increase the GU nor GI 
toxicity.  
   
 
